Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

<p>Supplementary TablesSupplementary Table 1: Patient and tumor sample informationSupplementary Table 2: Tumor mutation burdenSupplementary Table 3: Unfiltered whole exome sequencing mutation analysisSupplementary Table 4: Filtered whole exome sequencing mutation analysisSupplementary Table 5:...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Autor principal: H. Josh Jang (15206898) (author)
Outros Autores: Galen Hostetter (15053070) (author), Alexander W. Macfarlane (15206901) (author), Zachary Madaj (15206904) (author), Eric A. Ross (15019395) (author), Toshinori Hinoue (15206907) (author), Justin R. Kulchycki (15206910) (author), Ryan S. Burgos (15206913) (author), Mahvish Tafseer (15206916) (author), R. Katherine Alpaugh (15206919) (author), Candice L. Schwebel (15206922) (author), Rutika Kokate (15206925) (author), Daniel M. Geynisman (15206928) (author), Matthew R. Zibelman (15206931) (author), Pooja Ghatalia (15206934) (author), Peter W. Nichols (15206937) (author), Woonbok Chung (15206940) (author), Jozef Madzo (14923007) (author), Noah M. Hahn (15206943) (author), David I. Quinn (15012291) (author), Jean-Pierre J. Issa (15109358) (author), Michael J. Topper (15206946) (author), Stephen B. Baylin (15045804) (author), Hui Shen (10996894) (author), Kerry S. Campbell (9724036) (author), Peter A. Jones (14941116) (author), Elizabeth R. Plimack (15044781) (author)
Publicado em: 2025
Assuntos:
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
Descrição
Resumo:<p>Supplementary TablesSupplementary Table 1: Patient and tumor sample informationSupplementary Table 2: Tumor mutation burdenSupplementary Table 3: Unfiltered whole exome sequencing mutation analysisSupplementary Table 4: Filtered whole exome sequencing mutation analysisSupplementary Table 5: Immunohistochemistry scores of tumorsSupplementary Table 6: FACS panel for PBMC analysisSupplementary Table 7: Geometric mean fluorescence intensity (GMFI) from PBMC FACSSupplementary Table 8: Representativeness of Study Participants</p>